Policy & Regulation
Thrombosis Research Institute Announce ETHIC Trial to Evaluate the Potential Benefits of Early Administration of LMWH in Patients with COVID-19
30 June 2020 - - The UK-based Thrombosis Research Institute will conduct an open-label randomized controlled trial of community-based early thromboprophylaxis named ETHIC (Early Thromboprophylaxis in COVID-19), the organization said.

Eligible patients will have newly-diagnosed Covid-19 and also have been identified with an increased risk of complications of infection due to age and comorbidities.

The study was designed in response to recent evidence suggesting that severe COVID-19 infections are associated with increased frequency of thrombosis.

Symptomatic patients with COVID-19 receiving the LMWH (via enoxaparin) will be compared with patients receiving the standard of care.

The follow up period for assessing outcomes including hospitalization and mortality is at 21 days, with further assessments at 50 days and 90 days.

Symptomatic COVID-19 patients receiving the LMWH (via enoxaparin) will be compared with patients receiving the standard of care.

The follow up period for assessing outcomes including hospitalization and mortality is at 21 days, with further assessments at 50 days and 90 days.

The study will be funded by an investigator-initiated study grant provided by Sanofi.

The Thrombosis Research Institute is in innovative solutions for the detection and treatment of thrombosis. Sanofi is a global biopharmaceutical company focused on improving human health.
Login
Username:

Password: